

Data Set Name: *adverseevents.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	NEWAE_KEY	Char	11	\$11.	\$11.	AE key for linking new and continuing
3	AEDATE	Char	4	\$4.	\$4.	Date of AE
4	AEGRADE	Char	2	\$2.	\$2.	AE grade
5	AESER	Char	2	\$2.	\$2.	AE seriousness
6	AEPRESENT	Char	2	\$2.	\$2.	AE still present
7	AERELATED	Char	2	\$2.	\$2.	AE relatedness
8	ATFOLO	Char	5	\$5.	\$5.	AE measured at follow-up; recorded AE grade is the max grade during follow-up period
9	AERESOLVED	Char	2	\$2.	\$2.	AE resolved during follow-up period
10	AERESOLVEDDT	Char	2	\$2.	\$2.	AE resolved during follow-up period: date
11	MEDDRA	Char	8	\$8.	\$8.	AE MedDRA code

Data Set Name: alert.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	SITU DT	Num	8	BEST12.	BEST32.	Event Dates: Date of situation
3	PATSTAGE	Num	8	BEST12.	BEST32.	Patient stage of study at time of situation
4	SITU TYPE	Num	8	BEST12.	BEST32.	Event: Select one situation from below

Data Set Name: hemostatic.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	BLEEDIDENT	Num	8	BEST12.	BEST32.	Hemostatic assessment: Bleeding identified
3	BLEEDGRADE	Char	2	\$2.	\$2.	Hemostatic assessment: Grade
4	BLEEDDATE	Num	8	BEST12.	BEST32.	Daily form date
5	BLEEDLABEL	Char	43	\$43.	\$43.	SOC and grade label, derived from bleedgrade variable

Data Set Name: labs.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	LABTYPE	Char	27	\$27.	\$27.	Laboratory type
3	LABVALDT	Num	8	BEST12.	BEST32.	Laboratory values: Date
4	LABVALAMT	Num	8	BEST12.	BEST32.	Laboratory values: Amount
5	LABVALUNIT	Char	2	\$2.	\$2.	Laboratory values: Unit Type
6	LABVALMOD	Char	2	\$2.	\$2.	Lab value modifier

Data Set Name: otherefficacy.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	DAILYDT	Num	8	BEST12.	BEST32.	Daily form date
3	PHARMNOTDT	Char	2	\$2.	\$2.	Indicate changes in patient status: Pharmacy notified date
4	FIRSTDOSED	Char	2	\$2.	\$2.	Indicate changes in patient status: First dose date
5	URINALYSISDT	Char	4	\$4.	\$4.	Laboratory values: Urinalysis: date:
6	THROMBONSETDT	Char	3	\$3.	\$3.	Any thrombosis or thrombotic events identified: Date of onset symptoms per patient:
7	HOSPSTATUS	Num	8	BEST12.	BEST32.	Location of patient at start of day
8	ELIGIBILITYLOST	Char	2	\$2.	\$2.	Does the patient still meet inclusion/exclusion criteria
9	PATACTIVATION	Num	8	BEST12.	BEST32.	Indicate changes in patient status: Activation
10	DRUGSTOPREASON	Char	2	\$2.	\$2.	Reason for stopping study drug
11	PATTREATEND	Num	8	BEST12.	BEST32.	Indicate changes in patient status: Study dose treatment ended
12	DOSEINFOUNK	Num	8	BEST12.	BEST32.	Study medication doses: All study medication doses on hold
13	DOSESONHOLD	Num	8	BEST12.	BEST32.	Study medication doses
14	TREATTPA	Char	2	\$2.	\$2.	Current Treatment: TPA
15	TREATTRANS	Num	8	BEST12.	BEST32.	Current Treatment: Transplant today
16	TRANSTYPE	Char	2	\$2.	\$2.	Current Treatment: Transplant Type
17	DONORABO	Char	2	\$2.	\$2.	Current Treatment: Donor ABO
18	DONORRHFACTOR	Char	2	\$2.	\$2.	Current Treatment: Donor RH Factor
19	TREATCYTAR	Num	8	BEST12.	BEST32.	Current Treatment: Cytarabine (AraC)
20	TREATSTERIODS	Num	8	BEST12.	BEST32.	Current Treatment: Steroids
21	STERIODOPHTH	Char	2	\$2.	\$2.	Current Treatment: Steroids: Ophthalmic
22	STERIODSYSIV	Char	2	\$2.	\$2.	Current Treatment: Steroids: Systemic (IV/oral)
23	TREATNONE	Num	8	BEST12.	BEST32.	Current Treatment: None of the above
24	TREATTPAFOR	Char	2	\$2.	\$2.	Current Treatment: Alteplase given for
25	NOLABS	Num	8	BEST12.	BEST32.	Laboratory values: No labs drawn
26	ALLLABSENTERED	Num	8	BEST12.	BEST32.	Laboratory values: All lab data entered
27	DIPSTICK	Char	2	\$2.	\$2.	Laboratory values: Urinalysis: Dipstick result
28	URINVALMOD	Char	2	\$2.	\$2.	Urinalysis value modifier
29	NOPLATDRAWN	Num	8	BEST12.	BEST32.	Platelet count: No labs drawn
30	ALLPLATENTERED	Num	8	BEST12.	BEST32.	Platelet count: All platelet counts entered:
31	HADTRANSFUSION	Char	2	\$2.	\$2.	Transfusions
32	GRANTRANSFUSION	Num	8	BEST12.	BEST32.	Transfusions: Granulocyte Transfusion
33	PLATTRANSFUSION	Num	8	BEST12.	BEST32.	Transfusions: Platelet Transfusion
34	REDBLOODCELLTRANS	Num	8	BEST12.	BEST32.	Transfusions: Red Blood Cell Transfusion
35	RBCTNUMUNITS	Char	4	\$4.	\$4.	Transfusions: Number of units transfused
36	RBCTREAS	Char	2	\$2.	\$2.	Transfusions: Reason for transfusion

Num	Variable	Type	Len	Format	Informat	Label
37	URINALYSISINT	Char	2	\$2.	\$2.	Laboratory values: Urinalysis: interpretation
38	URINALYSISRBC	Char	3	\$3.	\$3.	Laboratory values: Urinalysis: Amount of RBCs
39	OCULARNOTDONE	Num	8	BEST12.	BEST32.	Ocular assessment: Assessment not done
40	OCDONEWITH	Char	2	\$2.	\$2.	Ocular assessment: Assessment done
41	RESNELLCHARTLT	Char	2	\$2.	\$2.	Right Eye: Ocular assessment: Snellen eye chart: Left
42	RESNELLCHARTRT	Char	3	\$3.	\$3.	Right Eye: Ocular assessment: Snellen eye chart: Right
43	REAMSLERGRID	Char	2	\$2.	\$2.	Right Eye: Ocular assessment: Amsler grid
44	REAMSQUADUL	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: Upper left
45	REAMSQUADUR	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: Upper right
46	REAMSQUADLL	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: Lower Left
47	REAMSQUADLR	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: Lower Right
48	REISHIHARA	Char	2	\$2.	\$2.	Right Eye: Ocular assessment: Amsler grid: Ishihara test - colorblindness was:
49	REISHPLATE1	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 01
50	REISHPLATE3	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 03
51	REISHPLATE4	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 04
52	REISHPLATE7	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 07
53	REISHPLATE8	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 08
54	REISHPLATE10	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 10
55	REISHPLATE12	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 12
56	REISHPLATE14	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 14
57	REISHPLATE16	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 16
58	REISHPLATE22	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 22
59	REISHPLATE25	Num	8	BEST12.	BEST32.	Right Eye: Ocular assessment: Amsler grid: 25
60	LEAMSQUADC	Char	2	\$2.	\$2.	Ocular assessment: left eye: center
61	REAMSQUADC	Char	2	\$2.	\$2.	Ocular assessment: right eye: center
62	THROMBEVENTS	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified
63	THRDIAGLINEOCCL	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: Line occlusion
64	LESNELLCHARTLT	Char	2	\$2.	\$2.	Left Eye: Ocular assessment: Snellen eye chart: Left
65	THRDIAGDVT	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: DVT
66	LESNELLCHARTRT	Char	3	\$3.	\$3.	Left Eye: Ocular assessment: Snellen eye chart: Right
67	THRDIAGCVT	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: Central venous thrombosis
68	LEAMSLERGRID	Char	2	\$2.	\$2.	Left Eye: Ocular assessment: Amsler grid
69	THRDIAGPE	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: PE
70	LEAMSQUADUL	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: Upper left
71	THRDIAGCVA	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: CVA
72	LEAMSQUADUR	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: Upper right

Num	Variable	Type	Len	Format	Informat	Label
73	THRDIAGMYOCARD	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: Myocardial Infarction
74	THRDIAGVOD	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified: Diagnosis: VOD (SOS)
75	LEAMSQUADLL	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: Lower Left
76	THRDIAGOTH	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: Diagnosis: Other
77	LEAMSQUADLR	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: Lower Right
78	LEISHIHARA	Char	2	\$2.	\$2.	Left Eye: Ocular assessment: Amsler grid: Ishihara test - colorblindness was:
79	THROMDOCXRAY	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: Chest X-ray
80	LEISHPLATE1	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 01
81	THROMDOCDOPLER	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: Doppler/Ultrasound
82	THROMDOCVENOG	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: Venography
83	LEISHPLATE3	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 03
84	THROMDOCMRI	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: MRI
85	LEISHPLATE4	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 04
86	THROMDOCCT	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: CT
87	THROMDOCDDIMER	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: D-dimer
88	DDIMERRESULTS	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: Results
89	LEISHPLATE7	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 07
90	THROMDOCOTH	Num	8	BEST12.	BEST32.	Any thrombosis or thrombotic events identified: How was the thrombotic event documented: Other
91	LEISHPLATE8	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 08
92	BLDSRCCHART	Num	8	BEST12.	BEST32.	Hemostatic assessment: Chart review (inpatient)
93	BLDSRCPABRS	Num	8	BEST12.	BEST32.	Hemostatic assessment: Patient assessment by research staff (inpatient)
94	LEISHPLATE10	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 10
95	BLDSRCPSS	Num	8	BEST12.	BEST32.	Hemostatic assessment: Patient self-assessment (outpatient)
96	ANYBLEED	Char	2	\$2.	\$2.	Hemostatic assessment: Any bleeding identified?
97	LEISHPLATE12	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 12
98	LEISHPLATE14	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 14
99	LEISHPLATE16	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 16
100	LEISHPLATE22	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 22
101	LEISHPLATE25	Num	8	BEST12.	BEST32.	Left Eye: Ocular assessment: Amsler grid: 25
102	CAENR	Num	8	BEST12.	BEST32.	Adverse events: Not reviewed
103	NONEWAE	Num	8	BEST12.	BEST32.	Adverse events: No new adverse events

Data Set Name: plateletcounts.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	PLATELETD	Num	8	BEST12.	BEST32.	Platelet count: date
3	PLATELETMOD	Char	2	\$2.	\$2.	Lab value modifier
4	PLATELETCOUNT	Num	8	BEST12.	BEST32.	Platelet count
5	PLATELETUNIT	Num	8	BEST12.	BEST32.	Platelet count: Unit

Data Set Name: *platelettransfusions.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	TRANSFPLATSRC	Char	2	\$2.	\$2.	Plat Transfusions: Platelet Source
3	PLATADDSOL	Char	2	\$2.	\$2.	Plat Transfusions: Platelet additive solution
4	PATHOGINACT	Char	2	\$2.	\$2.	Plat Transfusions: Pathogen inactivation
5	HLACOMPAT	Char	2	\$2.	\$2.	Plat Transfusions: HLA Compatible
6	CROSSMATCHCOMPAT	Char	2	\$2.	\$2.	Plat Transfusions: Cross-match compatible
7	TRANSFREASON	Char	2	\$2.	\$2.	Platelet Transfusions: Reason for tranfusion

Data Set Name: studydrug.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	STUDYDOSEAMT	Num	8	BEST12.	BEST32.	Study medication doses: Dose amount
3	STUDYDOSESRC	Char	2	\$2.	\$2.	Study medication doses: Source of study drug
4	DOSEDATE	Num	8	BEST12.	BEST32.	Daily form date

Data Set Name: subjectlevelvariables.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ID	Num	8	BEST12.	BEST32.	Anonymized participant ID
2	SCRNSTRTDT	Char	8	\$8.	\$8.	Screening info: Date screening started
3	CHEMOSTRTDT	Char	9	\$9.	\$9.	Primary diagnosis: Current/Planned Treatment: Start date
4	TRANSPLANTDT	Char	7	\$7.	\$7.	Primary diagnosis: Current/Planned Treatment: Planned transplant start date:
5	ESTROGENSTRTDT	Char	7	\$7.	\$7.	Primary diagnosis: Other medications: Estrogen start date
6	CYTARABADINESTRTDT	Char	8	\$8.	\$8.	Primary diagnosis: Other medications: cytarabidine start date
7	STEROIDSSTRTDT	Char	8	\$8.	\$8.	Primary diagnosis: Other medications: Steroids start date
8	TPATREATDT	Char	7	\$7.	\$7.	Primary diagnosis: Treatment: TPA: Start date
9	PLATCOUNTDT	Char	7	\$7.	\$7.	Platelet Count: Date
10	STUDYENDDT	Char	8	\$8.	\$8.	Study End Date
11	THROMBEVENTSDT	Char	10	\$10.	\$10.	Any thrombosis or thrombotic events identified: Date of review
12	END_THROMBONSETDT	Char	8	\$8.	\$8.	
13	FOLLOWUPDT	Char	7	\$7.	\$7.	Date of followup review
14	FOLO_THROMBONSETDT	Char	7	\$7.	\$7.	
15	ETHNICITY	Char	2	\$2.	\$2.	Demographics: Ethnicity
16	RACEOTHER	Char	2	\$2.	\$2.	Demographics: American-Indian/Alaska Native or Native Hawaiian/Pacific Islander or Unknown
17	RACEASIAN	Num	8	BEST12.	BEST32.	Demographics: Asian
18	RACEBL	Num	8	BEST12.	BEST32.	Demographics: Black/African-American
19	RACEWHITE	Num	8	BEST12.	BEST32.	
20	DISGROUP	Char	2	\$2.	\$2.	Disease group
21	AGE	Num	8	BEST12.	BEST32.	Demographics: age in years
22	INCLAGE	Num	8	BEST12.	BEST32.	Inclusion Criteria: Age >= 18 years of age
23	INCLDIAGHMA	Num	8	BEST12.	BEST32.	Inclusion Criteria: Confirmed diagnosis of a hematologic malignancy or aplasia
24	INCLUGCHEMO	Num	8	BEST12.	BEST32.	Inclusion Criteria: Undergoing or planned chemotherapy, immunotherapy or hematopoietic stem cell transplantation
25	INCLANTTHROM	Num	8	BEST12.	BEST32.	Inclusion Criteria: Anticipated to have hypoproliferative thrombocytopenia resulting in a platelet count of <= 10,000/micro L for >= 5 days
26	INCLABLECONS	Num	8	BEST12.	BEST32.	Inclusion Criteria: Able to provide informed consent and comply with treatment and monitoring, or having a Legally Authorized Representative (LAR)
27	EXCLDIAGLEUK	Num	8	BEST12.	BEST32.	Exclusion Criteria: Diagnosis of acute promyelocytic leukemia undergoing induction chemotherapy
28	EXCLHISTITP	Num	8	BEST12.	BEST32.	Exclusion Criteria: History of ITP, TTP or HUS

Num	Variable	Type	Len	Format	Informat	Label
29	EXCLVENTHROM	Num	8	BEST12.	BEST32.	Exclusion Criteria: Past history or current diagnosis of arterial or venous thromboembolic disease including acute coronary syndrome, peripheral vascular disease and retinal arterial or venous thrombosis (except when a prior history of central line thromb)
30	EXCLVENOCCL	Num	8	BEST12.	BEST32.	Exclusion Criteria: Diagnosis/previous history of veno-occlusive disease (also called sinusoidal obstruction syndrome)
31	EXCLBLEEDDIS	Num	8	BEST12.	BEST32.	Exclusion Criteria: Known inherited or acquired bleeding disorder including, but not limited to: Acquired storage pool deficiency or Paraproteinemia with platelet inhibition
32	EXCLPROTHROMB	Num	8	BEST12.	BEST32.	Exclusion Criteria: Known inherited or acquired prothrombotic disorders, including antiphospholipid syndrome. Those with lupus anticoagulant or positive antiphospholipid serology without thrombosis are not excluded.
33	EXCLDIC	Num	8	BEST12.	BEST32.	Exclusion Criteria: DIC according to the patients physician
34	EXCLALLERGYTXA	Num	8	BEST12.	BEST32.	Exclusion Criteria: Known allergy to tranexamic acid
35	EXCLASPARAG	Num	8	BEST12.	BEST32.	Exclusion Criteria: Receiving L-asparaginase as part of their current cycle of treatment
36	EXCLPROCOAG	Num	8	BEST12.	BEST32.	Exclusion Criteria: Receiving any pro-coagulant agents (e.g. DDAVP, recombinant Factor VIIa or Prothrombin Complex Concentrates (PCC) and/or an antifibrinolytic agent within 48 hours of enrollment
37	EXCLANTICOAG	Num	8	BEST12.	BEST32.	Exclusion Criteria: Receiving anticoagulant therapy or anti-platelet therapy (except when receiving prophylactic anticoagulant or low dose aspirin therapy for prophylaxis only with a plan to discontinue when the platelet count falls below 50,000)
38	EXCLDIALYSIS	Num	8	BEST12.	BEST32.	Exclusion Criteria: Receiving dialysis treatments
39	EXCLCREATININE	Num	8	BEST12.	BEST32.	Exclusion Criteria: Serum creatinine ≥ 5.7 mg/dL
40	EXCLANURIA	Num	8	BEST12.	BEST32.	Exclusion Criteria: Anuria (defined as urine output < 10 mls/hr over 24 hours)
41	EXCLOTHTRIAL	Num	8	BEST12.	BEST32.	Exclusion Criteria: Enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents
42	EXCLUNWBLD	Num	8	BEST12.	BEST32.	Exclusion Criteria: Unwilling to accept blood or blood component transfusions
43	EXCLPRIORRAND	Num	8	BEST12.	BEST32.	Exclusion Criteria: Prior randomization in this study at any stage of their treatment
44	EXCLMDREFUSE	Num	8	BEST12.	BEST32.	Exclusion Criteria: MD refused patient participation
45	EXCLKNHYP	Num	8	BEST12.	BEST32.	Exclusion Criteria: Known hypercoagulable state
46	EXCLPREGNURSE	Num	8	BEST12.	BEST32.	Exclusion Criteria: Pregnant or nursing or unwilling to use contraception during and for 30 days after taking the study drug (both males and females)
47	GENDER	Char	2	\$2.	\$2.	Demographics: Gender
48	THRDIAGCVA	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: CVA

Num	Variable	Type	Len	Format	Informat	Label
49	THRDIAGCVT	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: Central venous thrombosis
50	THRDIAGDVT	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: DVT
51	THRDIAGLINEOCCL	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: Line occlusion
52	THRDIAGMYOCARD	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: Myocardial Infarction
53	THRDIAGOTH	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: Other
54	THRDIAGPE	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: PE
55	THRDIAGVOD	Char	2	\$2.	\$2.	Any thrombosis or thrombotic events identified since last reported follow up: Diagnosis: VOD (SOS)
56	CONSSIGNED	Num	8	BEST12.	BEST32.	Consent signed
57	ELIGIBILITYLOST	Num	8	BEST12.	BEST32.	Does the patient still meet inclusion/exclusion criteria
58	DISEASE	Char	2	\$2.	\$2.	Primary diagnosis: Disease
59	TARGETIMMUN	Num	8	BEST12.	BEST32.	Primary diagnosis: Current/Planned Treatment: Targeted Immunotherapy
60	PRETRANSCHEMO	Num	8	BEST12.	BEST32.	Primary diagnosis: Current/Planned Treatment: Pre-Transplant Chemotherapy
61	RADIATION	Num	8	BEST12.	BEST32.	Primary diagnosis: Current/Planned Treatment: Radiation
62	CHEMOTHERAPY	Num	8	BEST12.	BEST32.	Primary diagnosis: Current/Planned Treatment: Chemotherapy
63	TRANSPLANT	Num	8	BEST12.	BEST32.	Primary diagnosis: Current/Planned Treatment: Planned transplant
64	ESTROGEN	Num	8	BEST12.	BEST32.	Primary diagnosis: Other medications: Estrogen
65	CYTARABADINE	Num	8	BEST12.	BEST32.	Primary diagnosis: Other medications: Cytarabine (AraC)
66	STEROIDS	Num	8	BEST12.	BEST32.	Primary diagnosis: Other medications: Steroids
67	STERIODOPHTH	Char	2	\$2.	\$2.	Other medication Steroids: Ophthalmic
68	STERIODSYSIV	Char	2	\$2.	\$2.	Other medication: Steroids: Systemic (IV/oral)
69	TPATREATMENT	Char	2	\$2.	\$2.	Primary diagnosis: Treatment: TPA
70	PATIENTABO	Char	2	\$2.	\$2.	Patient blood type: ABO Type
71	PATIENTRHFACOR	Char	2	\$2.	\$2.	Patient blood type: Rh Factor
72	NOPREADVEVENTS	Num	8	BEST12.	BEST32.	Current adverse events: No pre-existing adverse events
73	PLATCOUNTRESULT	Char	2	\$2.	\$2.	Platelet Count: Result
74	PLATCOUNTUNIT	Char	2	\$2.	\$2.	Platelet Count: Unit
75	ELIGCRITERIA	Char	2	\$2.	\$2.	Does the patient still meet eligibility criteria
76	PLATTRANSREQ	Char	2	\$2.	\$2.	Does the patient require a platelet transfusion threshold > 10,000/micro l
77	WHOBLEED	Char	2	\$2.	\$2.	Has the patient had WHO grade 2 bleeding in the past 48 hours?
78	URINALYSISNEG	Char	2	\$2.	\$2.	Is the most recent urinalysis within 72 hours and the result is negative for visible hematuria

Num	Variable	Type	Len	Format	Informat	Label
79	DISGROUP_1	Char	2	\$2.	\$2.	
80	ENDSTUDYSTAGE	Num	8	BEST12.	BEST32.	Patient stage of study
81	STUDYSTOPREASON	Num	8	BEST12.	BEST32.	Reason for stopping study
82	DEATHCAUSE	Char	2	\$2.	\$2.	Reason for stopping study: Presumed cause of death
83	PTSTAT120D	Char	2	\$2.	\$2.	Reason for stopping study: Patient status - only at 120 days
84	END_THROMBEVENTS	Char	2	\$2.	\$2.	
85	END_THRDIAGLINEOCCL	Num	8	BEST12.	BEST32.	
86	END_THRDIAGDVT	Num	8	BEST12.	BEST32.	
87	END_THRDIAGCVT	Num	8	BEST12.	BEST32.	
88	END_THRDIAGPE	Num	8	BEST12.	BEST32.	
89	END_THRDIAGCVA	Num	8	BEST12.	BEST32.	
90	END_THRDIAGMYOCARD	Num	8	BEST12.	BEST32.	
91	END_THRDIAGVOD	Char	2	\$2.	\$2.	
92	END_THRDIAGOTH	Num	8	BEST12.	BEST32.	
93	END_THROMDOCXRAY	Num	8	BEST12.	BEST32.	
94	END_THROMDOCDOPLER	Num	8	BEST12.	BEST32.	
95	END_THROMDOCVENOG	Num	8	BEST12.	BEST32.	
96	END_THROMDOCMRI	Num	8	BEST12.	BEST32.	
97	END_THROMDOCCT	Num	8	BEST12.	BEST32.	
98	END_THROMDOCDDIMER	Num	8	BEST12.	BEST32.	
99	END_THROMDOCOTH	Num	8	BEST12.	BEST32.	
100	NOFOLLOWUP	Char	2	\$2.	\$2.	Date of followup review: No follow up completed
101	NONEWAE	Char	2	\$2.	\$2.	Any adverse events identified since last reported follow up: No new adverse events
102	FOLO_THROMBEVENTS	Char	2	\$2.	\$2.	
103	FOLO_THRDIAGLINEOCCL	Char	2	\$2.	\$2.	
104	FOLO_THRDIAGDVT	Char	2	\$2.	\$2.	
105	FOLO_THRDIAGCVT	Char	2	\$2.	\$2.	
106	FOLO_THRDIAGPE	Char	2	\$2.	\$2.	
107	FOLO_THRDIAGCVA	Char	2	\$2.	\$2.	
108	FOLO_THRDIAGMYOCARD	Char	2	\$2.	\$2.	
109	FOLO_THRDIAGVOD	Char	2	\$2.	\$2.	
110	FOLO_THRDIAGOTH	Char	2	\$2.	\$2.	
111	FOLO_THROMDOCXRAY	Char	2	\$2.	\$2.	
112	FOLO_THROMDOCDOPLER	Char	2	\$2.	\$2.	
113	FOLO_THROMDOCVENOG	Char	2	\$2.	\$2.	
114	FOLO_THROMDOCMRI	Char	2	\$2.	\$2.	
115	FOLO_THROMDOCCT	Char	2	\$2.	\$2.	
116	FOLO_THROMDOCDDIMER	Char	2	\$2.	\$2.	

Num	Variable	Type	Len	Format	Informat	Label
117	FOLO_THROMDOCOTH	Char	2	\$2.	\$2.	
118	BLEED2	Char	2	\$2.	\$2.	Any WHO 2+ bleed within 30 days of activation
119	NUMPLT	Char	2	\$2.	\$2.	Platelet transfusions within 30 days of activation
120	DAYSNO2	Char	2	\$2.	\$2.	Days alive without WHO 2+ bleed within 30 days of activation
121	DAYSBLEEDTHROMB	Char	2	\$2.	\$2.	Days with bleeding or thrombocytopenia within 30 days of activation
122	DAYSTO2	Char	3	\$3.	\$3.	Days until first 2+ bleed or death (censor at 30)
123	HIBLEED	Char	2	\$2.	\$2.	Highest grade bleed within 30 days after activation
124	BLDDEATH	Char	5	\$5.	\$5.	Any Death due to Bleeding within 30 days
125	LOPLT	Char	2	\$2.	\$2.	Thrombocytopenic days within 30 days
126	BLEEDTRANS	Char	9	\$9.	\$9.	Days with bleeding and thrombocytopenia per thrombocytopenic day within 30 days
127	PLTTRANS	Char	9	\$9.	\$9.	Platelet transfusions per thrombocytopenic day within 30 days
128	REDTRANS	Char	10	\$10.	\$10.	RBC transfusions per thrombocytopenic day within 30 days
129	PLTDEATH	Char	2	\$2.	\$2.	Death or platelet transfusion within 30 days
130	RBCDEATH	Char	2	\$2.	\$2.	Death or RBC transfusion within 30 days
131	HIPLTNADIR	Char	5	\$5.	\$5.	Lowest platelet > 10 within 30 days
132	NUMTHROMB	Char	2	\$2.	\$2.	Thrombotic events within 120 days of activation (safety population)
133	VOD	Char	2	\$2.	\$2.	VOD within from activation to within 30 days after last dose (Safety population)
134	DEATH30	Char	5	\$5.	\$5.	Death within 30 days of activation (safety population)
135	DEATH120	Char	5	\$5.	\$5.	Death within 120 days of activation (safety population)
136	THROMBDEATH	Char	5	\$5.	\$5.	Death due to thrombosis within 120 days of activation
137	BMI	Char	3	\$3.	\$3.	Body Mass Index in kg/m ² [BioLINCC note: this field is provided as delivered - units and calculation used to produce this value are unclear.]
138	TREATMENT	Char	5	\$5.	\$5.	Treatment Arm: Indicates TXA arm or PBO arm